Ipamorelin vs CJC-1295: GHRP vs GHRH, and Why They’re Usually Stacked

Ipamorelin and CJC-1295 are the two halves of the most popular growth-hormone-secretagogue pairing in the peptide-research world. They are not competing options doing the same job — they act on two different receptors and are typically used together, not instead of each other. Ipamorelin (ipamorelin) is a selective growth-hormone-releasing peptide (GHRP) that mimics ghrelin at the GHS-R1a receptor; CJC-1295 (cjc-1295) is a growth-hormone-releasing-hormone (GHRH) analog that signals through the GHRH receptor.

TL;DR: Ipamorelin is a selective GHRP that triggers a clean, pulse-like growth-hormone release through the ghrelin receptor (GHS-R1a) without raising cortisol or prolactin. CJC-1295 is a GHRH analog that amplifies each GH pulse and sustains IGF-1. They hit different receptors, so most protocols combine them — GHRH primes, GHRP triggers. Neither is FDA-approved; both are research-use-only and WADA-prohibited.

Research-use & affiliate disclosure: This article is for educational and research purposes only and is not medical advice. Neither ipamorelin nor CJC-1295 is FDA-approved for human use; both are sold as research chemicals for laboratory research only. Dosing information reflects published research and community protocols, not clinical recommendations. VialBase may earn a commission from qualifying purchases made through vendor links on this page; this does not influence the research summarized here.

At a Glance

The single most common mistake is treating these as “two versions of the same thing.” They are not — they are complementary classes. Here is the side-by-side the rest of the article expands on.

The takeaway from that table: this is a GHRP-vs-GHRH comparison, and the honest answer to “which is better” is usually “both, together.” The interesting questions are what each contributes and when you would run one alone.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and a selective growth-hormone secretagogue — the first compound described as a selective GHS, in the landmark characterization by Raun and colleagues (Raun et al., 1998, PMID 9849822). It belongs to the GHRP class, the same functional family as GHRP-2 and GHRP-6, but its defining feature is selectivity: it releases GH with efficacy and potency comparable to GHRP-6, but without the accompanying ACTH, cortisol, and prolactin elevation that the older GHRPs cause — a selectivity confirmed at doses up to 1 mg/kg IV (Raun et al., 1998, PMID 9849822).

Mechanistically, ipamorelin binds the GHS-R1a receptor — the same receptor activated by endogenous ghrelin — on pituitary somatotrophs. Receptor binding activates phospholipase C → IP₃ → intracellular calcium release → exocytosis of stored GH granules. Recent pharmacology confirms ipamorelin acts as a GHS-R1a agonist in the ghrelin-receptor system (Lu et al., 2024, PMID 39043357).

Be precise about the evidence: ipamorelin’s selectivity is its best-documented property, established in early endocrine and medicinal-chemistry work (Raun et al., 1998, PMID 9849822; Hansen et al., 2001, PMID 11459660). Animal data also suggest GH-secretagogue effects on bone — in adult female rats, ipamorelin and GHRP-6 increased bone mineral content (Svensson et al., 2000, PMID 10828840). Most of the body-composition and “anti-aging” use, however, is extrapolated from GH/IGF-1 physiology and community practice rather than from completed human outcome trials. A 2026 critical review identifies ipamorelin as one of the most popular peptides among recreational athletes while noting that rigorous human efficacy data for performance are limited (Coutinho et al., 2026, PMID 41880199).

What Is CJC-1295?

CJC-1295 is a GHRH analog — a modified version of growth-hormone-releasing hormone, the hypothalamic peptide that signals the pituitary to release GH. Native GHRH is destroyed within minutes by the enzyme DPP-IV. CJC-1295 carries four amino-acid substitutions that block DPP-IV cleavage, extending its bioactive life. It comes in two functionally distinct forms:

• CJC-1295 no DAC (Mod GRF 1-29 / Modified GRF(1-29)): half-life ~30 minutes; produces discrete, pulse-like GH release. Most research protocols prefer this form for mimicking natural GH physiology.
• CJC-1295 with DAC (Drug Affinity Complex): the DAC modification covalently binds the peptide to circulating albumin, extending half-life to roughly 8 days and producing sustained GH elevation rather than pulses.

The key human pharmacokinetic finding comes from Teichman and colleagues: a long-acting GHRH analog (CJC-1295 with DAC) produced prolonged stimulation of GH and IGF-1 secretion in healthy adults, with IGF-1 elevated for days after a single subcutaneous dose (Teichman et al., 2006, PMID 16352683). That sustained-elevation property is exactly why some researchers prefer the DAC form for convenience — and exactly why others avoid it, since continuous elevation can blunt the natural pulsatile pattern the no-DAC form preserves.

CJC-1295’s evidence base is small — roughly 28 PubMed records — and is concentrated in early-phase pharmacokinetic work rather than large body-composition RCTs. A historical safety note: one death was reported during 2006 clinical trials of CJC-1295 with DAC, attributed to a pre-existing cardiac condition; the no-DAC formulation has not shown serious adverse events in the published literature. We treat that as a single, confounded case, not a demonstrated drug effect — but it is worth knowing.

The Core Difference: Two Receptors, One Pulse

This is the section most articles skip, and it is the entire point of the comparison.

GHRH primes; GHRP triggers

GH is released from the pituitary under two opposing controls: GHRH (the accelerator) stimulates release, and somatostatin (the brake) inhibits it. CJC-1295, as a GHRH analog, pushes the accelerator — it increases how much GH each pulse can deliver and raises IGF-1. Ipamorelin, as a GHS-R1a agonist, works on a separate pathway: it both stimulates GH release directly and helps suppress somatostatin, effectively releasing the brake.

Because they act on different receptors with partly independent and partly complementary signaling, combining a GHRH analog with a GHRP produces a GH pulse substantially larger than either compound alone — the pituitary is simultaneously primed (more GH available to release) and triggered (the release event fired) with the brake eased. This GHRH-plus-GHRP synergy is well-described in growth-hormone physiology and is the mechanistic basis for the standard stack.

Evidence-tier note. The synergy claim above is grounded in established GH neuroendocrinology and is reflected in narrative reviews of these peptides in sports and orthopaedic medicine (Rahman et al., 2026, PMID 41490200; Mayfield et al., 2026, PMID 41476424). We were unable to verify a specific human trial that directly measured the ipamorelin-plus-CJC-1295 combination versus each alone in a controlled setting; the “3-5x greater pulse” figures circulating in the community trace to GHRH+GHRP physiology generally, not to a confirmed head-to-head study. Treat the direction of the effect (synergy) as well-established and the exact multiplier as unverified.

Pulsatile vs sustained — why no-DAC is usually preferred

The body releases GH in pulses, and that pulsatility matters for receptor sensitivity. Ipamorelin is inherently pulsatile. CJC-1295 no-DAC is also pulsatile (~30-min half-life), which is why the no-DAC + ipamorelin combination is the most common research configuration — it amplifies natural pulses without flattening them. The DAC form’s multi-day sustained elevation (Teichman et al., 2006, PMID 16352683) trades physiologic pulsatility for convenience, and sustained elevation can downregulate GH-receptor sensitivity over time, which is the main argument against it.

Dosing & Administration

These are research-use figures reflecting commonly cited protocols, not medical advice. For the full protocol with per-vial unit math, see the CJC-1295 + Ipamorelin dosage chart.

Ipamorelin: 200-300 mcg per injection, 1-3x daily, subcutaneous on an empty stomach; bedtime dosing amplifies the natural deep-sleep GH pulse. Cycle 8-12 weeks on, ~4 weeks off.

CJC-1295 — no DAC (preferred): 100-300 mcg, 1-3x daily, same empty-stomach and timing rules. Cycle 8-12 weeks on, ~4 weeks off.

CJC-1295 — with DAC: 1,000-2,000 mcg, 2x weekly (sustained elevation; fewer injections).

The standard stack: ipamorelin + CJC-1295 no-DAC, often 100 mcg of each combined in the same syringe, dosed in the evening — the GHRH analog primes, the GHRP triggers. They are physically compatible in one injection.

Side Effects & Safety

Both are generally well tolerated at research doses. Ipamorelin has one of the cleanest profiles among GHRPs: mild injection-site reactions, a brief “head rush”/flushing, mild early water retention, and paresthesias from GH elevation — but no significant cortisol or prolactin elevation, the key advantage over GHRP-2 and GHRP-6 (Raun et al., 1998, PMID 9849822). CJC-1295 shares the GH-elevation class effects (water retention, paresthesias, possible headache); the DAC form’s sustained elevation is the main differentiator and can downregulate GH-receptor sensitivity. The single 2006 trial death (DAC form) was attributed to pre-existing cardiac disease with no causal link established.

Shared GH-axis contraindications (both): active malignancy (GH/IGF-1 can promote tumor growth), pregnancy/breastfeeding (no safety data), uncontrolled diabetes (GH is diabetogenic), and active pituitary tumors.

Quality-control caveat: these are unregulated research peptides. Underdosed, overdosed, or contaminated material is a more realistic risk than either peptide’s intrinsic toxicity. Third-party HPLC/MS testing with a batch-specific Certificate of Analysis is the most important safeguard.

Legality

Both occupy the same regulatory category: neither is FDA-approved for any human indication; both are prohibited under WADA S2 and will cause a positive doping test; neither is DEA-scheduled; and both are sold legally only as research chemicals for laboratory research use.

Which Should Researchers Consider?

The defensible call, by goal:

• For most GH-optimization research interest → both, stacked (ipamorelin + CJC-1295 no-DAC). This is the standard configuration; choosing “one or the other” usually means leaving the synergy on the table.
• If you want the single cleanest, best-documented compound → ipamorelin. Its selectivity (no cortisol/prolactin) is its best-established property.
• If sustained IGF-1 with minimal injections is the priority → CJC-1295 with DAC, accepting the trade-off of non-pulsatile exposure and possible GH-receptor downregulation.
• If preserving physiologic pulsatility matters → CJC-1295 no-DAC over DAC, ideally paired with ipamorelin.

For the typical reader, the honest bottom line is that ipamorelin and CJC-1295 are partners, not rivals — the comparison that matters is GHRP vs GHRH, and the answer for most protocols is “use one of each.” See the full CJC-1295 + Ipamorelin stack profile for mechanism synergy and evidence.

Frequently Asked Questions

What is the difference between ipamorelin and CJC-1295? They act on different receptors. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that triggers a GH pulse through the ghrelin receptor (GHS-R1a). CJC-1295 is a GHRH analog that amplifies pulse size and sustains IGF-1 through the GHRH receptor. They are complementary, not interchangeable, which is why they are usually stacked.

Should I take ipamorelin and CJC-1295 together? In most research protocols, yes — the GHRH analog primes the pituitary and the GHRP triggers release, producing a larger GH pulse than either alone. A common configuration is 100 mcg of each, combined in one syringe, dosed in the evening. The direction of the synergy is well-established in GH physiology; the exact multiplier often quoted is not from a confirmed head-to-head trial.

Is ipamorelin safer than CJC-1295? Ipamorelin has the cleaner documented profile because it does not raise cortisol or prolactin, unlike older GHRPs (Raun et al., 1998). CJC-1295’s main differentiator is the DAC form’s multi-day sustained GH elevation, which can downregulate receptor sensitivity. Both share GH-axis cautions (malignancy, pregnancy, uncontrolled diabetes), and both are research chemicals without long-term human safety data.

What is the difference between CJC-1295 with DAC and no DAC? No-DAC (Mod GRF 1-29) has a ~30-minute half-life and produces pulse-like GH release, preserving natural physiology. The DAC version binds to albumin, extending half-life to roughly 8 days and producing sustained elevation, which is more convenient (twice weekly) but less physiologic. Most researchers pair the no-DAC form with ipamorelin.

Are ipamorelin and CJC-1295 legal? Neither is FDA-approved for human use, and both are sold only as research chemicals for laboratory use. Neither is a DEA-controlled substance, but both are prohibited in sport under WADA category S2 and will cause a positive doping test. Competitive athletes should avoid both.

Do ipamorelin or CJC-1295 build muscle? Both raise GH and IGF-1, the hormones that mediate anabolic effects, and they are popular in the bodybuilding community for this reason. However, rigorous human trials demonstrating muscle or body-composition outcomes are lacking for both; a 2026 critical review notes the evidence for sports performance is limited (Coutinho et al., 2026). The strongest human data are for ipamorelin’s selectivity and CJC-1295’s GH/IGF-1 elevation, not for muscle-mass endpoints.

References

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822 — GH release comparable to GHRP-6 without ACTH/cortisol/prolactin elevation (selectivity hallmark).
• Lu Z, et al. GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiol Behav. 2024;284:114644. PMID 39043357 — confirms ipamorelin as a GHS-R1a agonist.
• Svensson J, et al. The GH secretagogues ipamorelin and GHRP-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID 10828840 — animal bone-mineral-content data.
• Hansen TK, et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett. 2001;11(15):1915-1918. PMID 11459660 — medicinal-chemistry characterization.
• Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683 — key human PK study for CJC-1295 (DAC).
• Rahman OF, et al. Therapeutic Peptides in Orthopaedics. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID 41490200 — narrative review covering CJC-1295 + ipamorelin.
• Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID 41476424 — clinician primer on injectable peptides.
• Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026. PMID 41880199 — context on popularity and limited human efficacy data.

Citations verified against the NCBI PubMed API. The GHRH+GHRP synergy is stated as established physiology (supported by review citations) rather than tied to an unverified head-to-head trial PMID, in line with VialBase citation policy.